Publication
Response to trametinib in recurrent low-grade serous ovarian cancer with NRAS mutation: A case report.
Authors not recorded
Gynecol Oncol Rep2019PMID 30809568PMC6374783stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (4)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 4
- cancerMalignant Ovarian Serous Tumorcivic_curation1.00
- drugTrametinibcivic_curation1.00
- geneNRAScivic_curation1.00
- variantNRAS Q61Kcivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 30809568
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| NRAS Q61K1 | ||||||||
| Trametinib | Malignant Ovarian Serous TumorALIAS | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID8933One 56 year old female with advanced recurrent low grade serous ovarian cancer with NRAS Q61K mutation had a partial response to trametinib, with short follow-up. PMID 30809568 · Champer et al., 2019 · Open in CIViC | civic |